COMP <GO>
ACHC vs CLOV // ENTERPRISE SCALE & MARKET CAP
Acadia Healthcare Company Inc. (NASDAQ) VS. Clover Health Investments Corp. (Class A) (NASDAQ) • 15-METRIC TALLY: ACHC 3
— CLOV 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ACHC
LAST: $29.46 (-0.17%) • MKT CAP: $2.74B
market-cap
$2.74B
LAST: $4.58 (-4.38%) • MKT CAP: $2.43B
market-cap
$2.43B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACHC VS. CLOV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACHC | CLOV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -24.80% | -29.30% | +4.50 | ACHC | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.04% | -2.84% | -13.20 | CLOV | /fcf-yield <GO> |
| Operating Margin | -40.60% | -4.40% | -36.20 | CLOV | /operating-margins <GO> |
| Net Profit Margin | -33.30% | -4.40% | -28.90 | CLOV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.00% | 40.30% | -35.30 | CLOV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 3.62 | -3.17 | CLOV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 3/9 | +2.00 | ACHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.3 | 49.5 | -2.20 | CLOV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.74B | $2.43B | $310.0M | ACHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACHC REV | CLOV REV | ACHC GROSS % | CLOV GROSS % | ACHC FCF | CLOV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.31B | $1.92B | — | — | -$439.9M | -$69.0M |
| FY 2024 | $3.15B | $1.37B | — | — | -$560.7M | $33.3M |
| FY 2023 | $2.93B | $1.26B | — | — | $330.5M | -$144.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACHC // BETA 1.07
CLOV // BETA —